NOW ENROLLING IN RENAL CELL CARCINOMA

PHASE 3 (NCT03729245)

PIVOT-09: Bempegaldesleukin with nivolumab in patients with advanced renal cell carcinoma (RCC)

A randomized study of bempegaldesleukin (BEMPEG; NKTR-214) in combination with nivolumab (NIVO) compared with the investigator's choice of tyrosine kinase inhibitor therapy (either sunitinib or cabozantinib) for previously untreated advanced RCC[1]

ENROLL NOW
Scan here to find out more about this clinical study at ClinicalTrials.gov

POPULATION

- Previously untreated advanced RCC
- Any IMDC prognostic score
- Tumor tissue available for PD-L1 testing

N≈600

R

BEMPEG + NIVO

Investigator's choice of **sunitinib** or **cabozantinib**

CO-PRIMARY ENDPOINTS

- Objective response rate
- Overall survival

KEY SECONDARY ENDPOINTS

- Progression-free survival
- Safety and tolerability

Bempegaldesleukin is an investigational, first-in-class, CD122-preferential, IL-2–pathway agonist[2]

Nivolumab is a PD-1 blocking antibody[3]

BEMPEG, bempegaldesleukin (NKTR-214); IL, interleukin; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; NIVO, nivolumab; PD-1, programmed death-1; PD-L1, programmed death-ligand 1; RCC, renal cell carcinoma.

1. ClinicalTrials.gov. NCT03729245. https://clinicaltrials.gov/ct2/show/NCT03729245. Accessed September 3, 2020. 2. Charych DH, *et al. Clin Cancer Res* 2016;22:680–690.
3. Opdivo (nivolumab) Prescribing Information (Princeton, NJ: Bristol Myers Squibb; revised: June 2020).

ACTIVE CLINICAL TRIALS WITH BEMPEGALDESLEUKIN AND NIVOLUMAB

NEKTAR

Bristol Myers Squibb™

Bempegaldesleukin (BEMPEG; NKTR-214) in combination with nivolumab (NIVO) leverages two immuno-oncology pathways with the aim of addressing the unmet needs of patients living with cancer

FIND OUT MORE
Scan here to discover more about BEMPEG at Nektar.com
or email medicalaffairs@nektar.com



BEMPEG, bempegaldesleukin (NKTR-214); NIVO, nivolumab.

FOR EDUCATIONAL PURPOSES ONLY.

This compound and the combinations of agents and their uses have not been approved.